
AstraZeneca moves finance chief to new role after Alexion deal
AstraZeneca (AZN.L) will move finance chief Marc Dunoyer to head newly acquired rare diseases business Alexion (ALXN.O), using the $39 billion takeover as an opportunity to freshen up a management team that had been in place for eight years.
















